Welcome to our dedicated page for Cosmos Health news (Ticker: COSM), a resource for investors and traders seeking the latest updates and insights on Cosmos Health stock.
Cosmos Health Inc. reports developments across a vertically integrated healthcare platform that includes wholesale pharmaceutical distribution, contract manufacturing, proprietary nutraceutical brands and research and development. Recurring updates cover U.S. commercialization of the 18 Series nutraceutical portfolio, including Noor18, Liv18, Cur18 and Fort18, as well as Sky Premium Life orders, international distribution relationships and product launches.
Company news also covers financial results, margin and revenue drivers at Cana Laboratories, CosmoFarm and Decahedron, AI investments including the Cloudscreen drug-repurposing platform, and Nasdaq listing-compliance or governance matters tied to its common stock.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Cosmos Health Inc. (NASDAQ:COSM) announced its fiscal year 2022 results, reporting revenues of $50.3 million, a decline from $56.2 million in FY2021 primarily due to foreign exchange variations. However, on a constant currency basis, revenue growth was noted at 0.71%. The company achieved positive Adjusted EBITDA of $0.5 million and significantly improved its financial position, ending 2022 with approximately $21 million in cash and long-term debt reduced by 76% to $5.1 million. Cosmos raised $56.5 million from equity offerings and warrant exercises. Amid market challenges, the CEO praised the company's strong performance and outlined plans for growth through acquisitions, including Cana Laboratories and ZipDoctor, enhancing the company’s vertical integration and entry into telehealth.
Cosmos Health (Nasdaq:COSM) announced its participation in The Economist Annual New York-Eastern Mediterranean Business Summit on July 10th, 2023, at the Lotte Palace, New York. CEO Greg Siokas will deliver a speech, partake in a Q&A, and engage in discussions about investment opportunities in the Eastern Mediterranean. The summit aims to explore the region's business potential with prominent speakers from the US, Israel, Greece, and Cyprus. Attendees include executives from various industries and institutional investors. This event highlights Cosmos Health's commitment to innovation, product development, and international expansion.